Marinus Pharmaceuticals (NASDAQ:MRNS) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.
A number of other research analysts also recently weighed in on MRNS. ValuEngine upgraded shares of Marinus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. JMP Securities restated an “outperform” rating and set a $11.00 price objective (up previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Tuesday, September 12th.
Marinus Pharmaceuticals (MRNS) opened at $7.86 on Thursday. Marinus Pharmaceuticals has a 52-week low of $0.82 and a 52-week high of $8.90.
Institutional investors have recently modified their holdings of the stock. Jennison Associates LLC raised its position in Marinus Pharmaceuticals by 108.1% in the second quarter. Jennison Associates LLC now owns 811,665 shares of the biopharmaceutical company’s stock worth $1,112,000 after acquiring an additional 421,600 shares during the period. EAM Investors LLC bought a new position in Marinus Pharmaceuticals in the third quarter worth approximately $554,000. Granite Point Capital Management L.P. raised its position in Marinus Pharmaceuticals by 250.3% in the third quarter. Granite Point Capital Management L.P. now owns 2,684,848 shares of the biopharmaceutical company’s stock worth $15,760,000 after acquiring an additional 1,918,400 shares during the period. KCG Holdings Inc. raised its position in Marinus Pharmaceuticals by 29.5% in the first quarter. KCG Holdings Inc. now owns 64,539 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 14,692 shares during the period. Finally, Perceptive Advisors LLC bought a new position in Marinus Pharmaceuticals in the third quarter worth approximately $8,527,000. Institutional investors own 49.77% of the company’s stock.
Marinus Pharmaceuticals Company Profile
Marinus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Receive News & Ratings for Marinus Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.